The UK-based life sciences investment firm Syncona announced a strategic restructuring and a shift toward establishing a new evergreen fund vehicle, aiming to navigate the ongoing bleak biotech financing environment. This move follows challenges in public markets and reflects a pragmatic approach to portfolio returns and long-term sustainability. Syncona’s refocused investment strategy prioritizes supporting portfolio companies through turbulent market conditions while seeking innovative avenues for capital deployment away from traditional public market exposure.